360iResearch
Talk to an analyst

Market research

AI in clinical Trials Market

Report reference
MRR-03559044807A
Published
Geographic coverage
Global
Explore licenses

Assess the study’s coverageRead the public overview, then compare the chapter outline with your research brief.

25report chapters

360iResearch introduction

Public research overview

AI Is Reshaping Clinical Trial Design, Delivery, and Evidence Generation

Artificial intelligence is becoming an enabling layer across clinical-trial planning, patient identification, recruitment, site selection, trial operations, safety monitoring, data management, and regulatory documentation. Its value is greatest where fragmented data, complex eligibility criteria, and operational delays create avoidable friction. Adoption remains dependent on data quality, validation, privacy protection, explainability, and the ability to demonstrate that AI-supported decisions preserve scientific and ethical standards.

Inside the research

Coverage at a glance

Selected branches from the published table of contents. Follow a chapter to see every subchapter in context.

  1. Chapter 7 Offering Type

    • Software and Model Access
    • AI-Enabled Research Services
    • Implementation and Support Services
    View chapter

  2. Chapter 8 AI Model Architecture

    • Machine Learning
    • Hybrid Learned and Symbolic AI
    • Symbolic AI
    View chapter

  3. Chapter 9 Generative AI Usage

    • Exclusively Non-Generative AI
    • Generative AI Enabled
    View chapter
Explore all chapters

Clinical Trials Are Moving Toward More Adaptive, Data-Driven Operations

The clinical-trial landscape is shifting from largely manual, sequential workflows toward integrated processes that use real-world data, electronic health records, medical imaging, laboratory information, and patient-generated data. AI can help identify eligible participants, anticipate recruitment barriers, optimize monitoring priorities, and detect inconsistencies earlier. These changes are also increasing the importance of interoperability, common data models, prospective validation, human oversight, and documented accountability throughout the trial lifecycle.

AI’s Cumulative Impact Depends on Trustworthy Integration, Not Isolated Automation

AI can improve trial efficiency by reducing repetitive work and supporting faster analysis, but its cumulative impact depends on how well tools operate across connected workflows. Benefits may be limited by biased training data, missing data, inconsistent clinical coding, model drift, cybersecurity risks, and unclear responsibility for decisions. Successful deployment therefore combines algorithmic performance with governance, auditability, clinician and investigator review, participant transparency, and continuous monitoring after implementation.

Regional Readiness Varies With Data Infrastructure, Regulation, and Trial Ecosystems

North America benefits from mature research networks, extensive clinical data resources, and strong investment in digital health, while facing demanding privacy, evidentiary, and regulatory expectations. Europe combines advanced biomedical capabilities with a highly structured privacy and governance environment, making cross-border data access and harmonization central concerns. Asia-Pacific is supported by expanding digital infrastructure and diverse patient populations, but implementation varies substantially across jurisdictions. Latin America is developing AI-enabled research capacity while contending with uneven infrastructure and data fragmentation. The Middle East is investing in digital transformation and centralized health systems, whereas Africa presents significant opportunities for inclusive recruitment and locally relevant evidence alongside persistent connectivity, data availability, and workforce constraints.

International Groupings Highlight Different Priorities for AI Governance and Trial Collaboration

ASEAN countries are likely to prioritize interoperable systems and practical coordination across diverse regulatory and health infrastructures. BRICS members span major research capabilities and emerging trial environments, creating opportunities for collaboration while requiring careful alignment of data, ethics, and regulatory practices. The European Union emphasizes privacy, harmonized oversight, and trustworthy AI. G7 members generally combine advanced research ecosystems with stringent governance expectations. GCC countries can leverage coordinated health systems and digital investment, while NATO members may place additional emphasis on resilience, cybersecurity, secure data exchange, and continuity of critical research operations.

Country Context Determines How AI Can Be Validated and Scaled in Clinical Research

Australia and Canada offer strong research institutions and public health data assets, with governance and jurisdictional coordination remaining important. Brazil, Mexico, India, and South Africa can benefit from broader and more representative recruitment but must address infrastructure variation, data quality, and workforce capacity. China, Japan, and South Korea have substantial technology and research capabilities, with interoperability, regulatory alignment, and responsible data use shaping deployment. France, Germany, Italy, Spain, and the United Kingdom combine established trial networks with detailed privacy and evidence requirements. Russia’s research environment is influenced by data access, international collaboration, and regulatory conditions. Across the United States, AI adoption is supported by deep clinical research capabilities, while fragmented systems and compliance obligations require robust validation and oversight.

Industry Leaders Should Build Governed AI Capabilities Around Measurable Trial Outcomes

Leaders should begin with high-friction use cases where performance can be measured, such as feasibility assessment, recruitment support, data cleaning, and risk-based monitoring. Establish clear ownership for model development, validation, deployment, and incident response; maintain traceable documentation; and require human review for consequential decisions. Investments should prioritize interoperable data foundations, representative datasets, privacy-preserving methods, cybersecurity, staff training, and participant communication. Partnerships with investigators, patients, regulators, and technology specialists should be structured around transparent validation protocols rather than demonstrations alone.

Methodology Combines Secondary Evidence, Workflow Analysis, and Cross-Market Comparison

This executive summary applies a structured review of publicly available regulatory materials, peer-reviewed research, clinical-trial practices, digital-health standards, and documented implementation patterns. Findings are organized across the trial lifecycle and compared by region, international grouping, and country to identify recurring opportunities, constraints, and governance requirements. Interpretations are limited to evidence-supported themes; where national conditions differ, the analysis reflects variation in infrastructure, regulation, data access, research capacity, and health-system organization rather than assuming uniform adoption.

Responsible Integration Will Determine AI’s Long-Term Role in Clinical Trials

AI can strengthen clinical trials by supporting better targeting, more efficient operations, improved data quality, and earlier identification of risks. Its durable contribution will depend on evidence of real-world usefulness, equitable performance, secure data practices, and transparent accountability. Organizations that pair innovation with rigorous validation and participant-centered governance will be better positioned to translate AI capabilities into reliable, ethical, and clinically meaningful research outcomes.

Research report

Table of contents

  1. 1.Preface
    1. 1.1Objectives of the Study
    2. 1.2Market Definition
    3. 1.3Market Segmentation & Coverage
    4. 1.4Years Considered for the Study
    5. 1.5Currency Considered for the Study
    6. 1.6Language Considered for the Study
    7. 1.7Key Stakeholders
  2. 2.Research Methodology
    1. 2.1Introduction
    2. 2.2Research Design
      1. 2.2.1Primary Research
      2. 2.2.2Secondary Research
    3. 2.3Research Framework
      1. 2.3.1Qualitative Analysis
      2. 2.3.2Quantitative Analysis
    4. 2.4Market Size Estimation
      1. 2.4.1Top-Down Approach
      2. 2.4.2Bottom-Up Approach
    5. 2.5Data Triangulation
    6. 2.6Research Outcomes
    7. 2.7Research Assumptions
    8. 2.8Research Limitations
  3. 3.Executive Summary
    1. 3.1Introduction
    2. 3.2CXO Perspective
    3. 3.3New Revenue Opportunities
    4. 3.4Next-Generation Business Models
    5. 3.5Industry Roadmap
  4. 4.Market Overview
    1. 4.1Introduction
    2. 4.2Industry Ecosystem & Value Chain Analysis
      1. 4.2.1Supply-Side Analysis
      2. 4.2.2Demand-Side Analysis
      3. 4.2.3Stakeholder Analysis
    3. 4.3Market Dynamics
      1. 4.3.1Key Drivers
        1. 4.3.1.1Modernized clinical-trial standards
        2. 4.3.1.2Growth in trial-data complexity
        3. 4.3.1.3Expansion of distributed trial delivery
        4. 4.3.1.4Broader AI capability coverage
      2. 4.3.2Key Restraints
        1. 4.3.2.1Validation and credibility burden
        2. 4.3.2.2Privacy, security, and data-right constraints
        3. 4.3.2.3Fragmented data and system landscape
        4. 4.3.2.4Organizational readiness requirements
      3. 4.3.3Key Opportunities
        1. 4.3.3.1Generative workflow augmentation
        2. 4.3.3.2Integrated trial platforms
        3. 4.3.3.3Geographic localization and expansion
        4. 4.3.3.4AI assurance and managed services
      4. 4.3.4Key Challenges
        1. 4.3.4.1Model reliability and traceability
        2. 4.3.4.2Context-specific evidence requirements
        3. 4.3.4.3Cross-border operational coordination
        4. 4.3.4.4Fit-for-purpose data access
    4. 4.4Porter’s Five Forces Analysis
    5. 4.5PESTLE Analysis
    6. 4.6Market Outlook
      1. 4.6.1Near-Term Market Outlook (0–2 Years)
      2. 4.6.2Medium-Term Market Outlook (3–5 Years)
      3. 4.6.3Long-Term Market Outlook (5–10 Years)
    7. 4.7Go-to-Market Strategy
  5. 5.Market Insights
    1. 5.1Consumer Insights & End-User Perspective
    2. 5.2Consumer Experience Benchmarking
    3. 5.3Opportunity Mapping
    4. 5.4Distribution Channel Analysis
    5. 5.5Pricing Trend Analysis
    6. 5.6Regulatory Compliance & Standards Framework
    7. 5.7ESG & Sustainability Analysis
    8. 5.8Disruption & Risk Scenarios
    9. 5.9Return on Investment & Cost-Benefit Analysis
  6. 6.Cumulative Impact of Artificial Intelligence 2026
  7. 7.AI in clinical Trials Market, by Offering Type
    1. 7.1Introduction
    2. 7.2Software and Model Access
    3. 7.3AI-Enabled Research Services
      1. 7.3.1AI-Enabled Trial Operations Services
      2. 7.3.2AI Analytical Services
    4. 7.4Implementation and Support Services
  8. 8.AI in clinical Trials Market, by AI Model Architecture
    1. 8.1Introduction
    2. 8.2Machine Learning
      1. 8.2.1Neural Networks and Deep Learning
      2. 8.2.2Non-Neural Machine Learning
    3. 8.3Hybrid Learned and Symbolic AI
    4. 8.4Symbolic AI
  9. 9.AI in clinical Trials Market, by Generative AI Usage
    1. 9.1Introduction
    2. 9.2Exclusively Non-Generative AI
    3. 9.3Generative AI Enabled
  10. 10.AI in clinical Trials Market, by AI Input Modality
    1. 10.1Introduction
    2. 10.2Structured Clinical and Operational Data
    3. 10.3Text and Documents
    4. 10.4Images and Video
    5. 10.5Multimodal Data
    6. 10.6Molecular Sequences and Omics Profiles
    7. 10.7Audio and Sensor Time Series
  11. 11.AI in clinical Trials Market, by Application
    1. 11.1Introduction
    2. 11.2Participant Identification and Recruitment
    3. 11.3Clinical Data Acquisition and Management
    4. 11.4Trial Analysis and Interpretation
    5. 11.5Endpoint and Biomarker Measurement
    6. 11.6Trial Design and Feasibility
    7. 11.7Integrated Multiworkflow Applications
    8. 11.8Trial Operations and Quality Oversight
    9. 11.9Clinical Documentation and Reporting
    10. 11.10Site and Investigator Selection
    11. 11.11Participant Engagement, Adherence and Retention
    12. 11.12Clinical Supply Planning
    13. 11.13Trial Safety Review
  12. 12.AI in clinical Trials Market, by Buyer Type
    1. 12.1Introduction
    2. 12.2Pharmaceutical and Biotechnology Companies
    3. 12.3CROs and Specialized Trial-Service Providers
    4. 12.4Research Sites and Healthcare Providers
      1. 12.4.1Hospitals, Health Systems and Care Practices
      2. 12.4.2Independent Research Sites and Site Networks
    5. 12.5Medical Technology and Digital Health Companies
    6. 12.6Academic, Governmental and Nonprofit Research Organizations
    7. 12.7Nutrition and Consumer Health Companies
  13. 13.AI in clinical Trials Market, by Therapeutic Area
    1. 13.1Introduction
    2. 13.2Oncology
    3. 13.3Neurological Disorders
    4. 13.4Cardiovascular Disorders
    5. 13.5Cross-Therapeutic Trials and Programs
    6. 13.6Endocrine, Nutritional and Metabolic Disorders
    7. 13.7Psychiatric, Neurodevelopmental and Sleep Disorders
    8. 13.8Digestive, Hepatic and Oral Disorders
    9. 13.9Blood and Immune System Disorders
    10. 13.10Infectious and Parasitic Diseases
    11. 13.11Respiratory Disorders
    12. 13.12Musculoskeletal and Connective Tissue Disorders
    13. 13.13Ophthalmic and Otologic Disorders
    14. 13.14Renal, Urological and Reproductive Disorders
    15. 13.15Dermatological Disorders
    16. 13.16Healthy-Volunteer and General Health Studies
    17. 13.17Maternal, Perinatal and Congenital Conditions
    18. 13.18Symptom and Functional Health Studies
    19. 13.19Injuries, Poisoning and Procedural Complications
  14. 14.AI in clinical Trials Market, by Software Deployment Model
    1. 14.1Introduction
    2. 14.2Cloud Deployment
    3. 14.3Hybrid Deployment
    4. 14.4Non-Cloud Deployment
  15. 15.AI in clinical Trials Market, by Trial Delivery Model
    1. 15.1Introduction
    2. 15.2Site-Based Trials
    3. 15.3Hybrid Trials
    4. 15.4Cross-Model Trial Programs
    5. 15.5Fully Decentralized Trials
  16. 16.AI in clinical Trials Market, by Route to Market
    1. 16.1Introduction
    2. 16.2Supplier-Direct Sales
    3. 16.3Reseller and Distributor Sales
    4. 16.4Marketplace Transactions
  17. 17.AI in clinical Trials Market, by Pricing Basis
    1. 17.1Introduction
    2. 17.2Subscription and License Fees
    3. 17.3Fixed Study and Project Fees
    4. 17.4Time-and-Materials Fees
    5. 17.5Usage-Based Fees
    6. 17.6Outcome-Contingent Fees
  18. 18.AI in clinical Trials Market, by Trial Phase
    1. 18.1Introduction
    2. 18.2Phase 3
    3. 18.3Phase 2
    4. 18.4Cross-Phase Trial Programs
    5. 18.5Phase 1
    6. 18.6Unphased Interventional Trials
    7. 18.7Combined-Phase Trials
    8. 18.8Phase 4
    9. 18.9Early Phase 1
  19. 19.AI in clinical Trials Market, by Intervention Type
    1. 19.1Introduction
    2. 19.2Drug Products
    3. 19.3Biological and Genetic Therapies
    4. 19.4Medical Devices
    5. 19.5Cross-Intervention Trial Programs
    6. 19.6Behavioral and Educational Interventions
    7. 19.7Multi-Class Intervention Trials
    8. 19.8Diagnostic Interventions
    9. 19.9Care Delivery and Environmental Interventions
    10. 19.10Procedural and Radiation Interventions
    11. 19.11Nutrition and Nonmedicinal Consumer Products
  20. 20.AI in clinical Trials Market, by Region
    1. 20.1Introduction
    2. 20.2North America
    3. 20.3Europe
    4. 20.4Asia-Pacific
    5. 20.5Latin America
    6. 20.6Middle East
    7. 20.7Africa
  21. 21.AI in clinical Trials Market, by Group
    1. 21.1Introduction
    2. 21.2NATO
    3. 21.3G7
    4. 21.4European Union
    5. 21.5BRICS
    6. 21.6ASEAN
    7. 21.7GCC
  22. 22.AI in clinical Trials Market, by Country
    1. 22.1Introduction
    2. 22.2United States
    3. 22.3China
    4. 22.4Germany
    5. 22.5India
    6. 22.6Japan
    7. 22.7United Kingdom
    8. 22.8France
    9. 22.9Canada
    10. 22.10Australia
    11. 22.11South Korea
    12. 22.12Spain
    13. 22.13Italy
    14. 22.14Brazil
    15. 22.15Russia
    16. 22.16Mexico
  23. 23.Competitive Landscape
    1. 23.1Market Share Analysis, 2025
    2. 23.2Market Concentration Analysis, 2025
      1. 23.2.1Concentration Ratio (CR)
      2. 23.2.2Herfindahl Hirschman Index (HHI)
    3. 23.3Recent Developments & Impact Analysis, 2025
    4. 23.4Product Portfolio Analysis, 2025
    5. 23.5Benchmarking Analysis, 2025
  24. 24.Company Profiles
    1. 24.1IQVIA Holdings Inc.
    2. 24.2Medidata
    3. 24.3ICON plc
    4. 24.4Parexel International Corporation
    5. 24.5Thermo Fisher Scientific Inc.
    6. 24.6Oracle Corporation
    7. 24.7Veeva Systems Inc.
    8. 24.8Fortrea Holdings Inc.
    9. 24.9Saama, LLC
    10. 24.10Medable Inc.
    11. 24.11Tempus AI, Inc.
    12. 24.12ConcertAI
    13. 24.13Unlearn.ai, Inc.
    14. 24.14Owkin, Inc.
    15. 24.15Phesi, Inc.
    16. 24.16QuantHealth Ltd.
    17. 24.17Certara, Inc.
    18. 24.18eClinical Solutions LLC
    19. 24.19Zhejiang Taimei Medical Technology Co., Ltd.
    20. 24.20HEALWELL AI Inc.
    21. 24.21Trialbee AB
    22. 24.22Impatients N.V.
    23. 24.23Averbis GmbH
    24. 24.24Quibim
    25. 24.25Clinion AI Technologies Pvt Ltd
    26. 24.26Yidu Tech
    27. 24.27Deep Intelligent Particle (Beijing) Technology Co., Ltd.
    28. 24.28Lunit
    29. 24.29Oncoshot
    30. 24.30Paradigm Health Inc.
    31. 24.31CluePoints
    32. 24.32AiCure
    33. 24.33Signant Health
    34. 24.34ProofPilot
    35. 24.35PhaseV
    36. 24.36Inato
    37. 24.37Lindus
    38. 24.38Yseop
    39. 24.39IXICO plc
    40. 24.40Qureight Ltd
    41. 24.41PathAI, Inc.
    42. 24.42Nucleai
    43. 24.43TriNetX
    44. 24.44Flatiron Health
    45. 24.45Syneos Health
    46. 24.46Florence Healthcare
    47. 24.47SAS Institute Inc.
    48. 24.48Massive Bio, Inc.
    49. 24.49TrialX
    50. 24.50H1 Insights, Inc.
    51. 24.51AutoCruitment
  25. 25.Key Experts

Loading the sample request form…